Moreover, several recent findings support ABCB1 and ABCG2-mediated efflux of asciminib, a new drug in development in CML, as the mechanism of resistance in these cell lines (10, 11). The gene discussed is ABCB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.